Tscan Therapeutics EBIT

Tscan Therapeutics (TCRX) currently reports a EBIT of $-130M as of March 2026. That compares with $-140M in the prior-year period — up 7.7% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Tscan Therapeutics's EBIT history and peer comparisons.

Tscan Therapeutics's EBIT increased from $-140M to $-130M — a 7.7% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tscan Therapeutics's EBIT of $-130M is lower than the Healthcare sector average of $23B. That is roughly 100.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Tscan Therapeutics reported $-130M in EBIT as of March 2026. That compares with $-140M in the prior-year period — up 7.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-130M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Tscan Therapeutics, and consider following TCRX for alerts when major investors trade the stock.